MDMA NDA resubmission returns to the FDA in August 2026 as sponsors seek renewed review after prior setback in the US drug approval process

MDMA-assisted therapy has re-entered the US regulatory pipeline after an NDA resubmission to the FDA in August 2026. The move signals a renewed attempt to win approval for a treatment model centered on MDMA, likely following earlier regulatory resistance, data disputes, or concerns about trial design, safety monitoring, and therapist-dependent outcomes. FDA review now matters not only for one product application but for the broader psychedelic medicine sector. A fresh filing can reset timelines for advisory scrutiny, labeling negotiations, risk management requirements, and commercial planning, while also shaping expectations for investors, clinics, therapists, and patients waiting for a legal pathway. MDMA remains one of the most closely watched psychedelic-adjacent compounds in medicine because its approval status could influence how regulators handle psychotherapy-linked drug applications, post-approval safeguards, and evidentiary standards across the field.